Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
about
Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvementExpert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaPhase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.Maintaining bone health in patients with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease.Genetic factors influencing the risk of multiple myeloma bone diseaseMicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma.Pomalidomide: a review of its use in patients with recurrent multiple myeloma.Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells.A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progressionImmunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.Pomalidomide in the treatment of relapsed multiple myeloma.JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide.Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple MyelomaLenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory propertiesTrial Watch: Lenalidomide-based immunochemotherapy.Thalidomide promotes transplanted cell engraftment in the rat liver by modulating inflammation and endothelial integrity.LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic RegimensOsteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1A Novel Green Synthesis of Thalidomide and Analogs
P2860
Q27011865-B2CB581B-E4D9-4D54-950B-157DC02EACF3Q33413142-E56C9BB4-ADF0-42D6-8A55-F063D5E03658Q33437811-35CA6DCB-A4A4-45BD-93B3-01D6C7BD1CB5Q34307388-5054FA66-10F8-4384-A1B9-FE44A0CC948CQ34423112-3025F8F4-C0C1-4EDC-9106-3B1A3BBC1D2AQ34674841-1B463F45-B411-41B4-857F-E9240574B092Q35766816-BE37E2FB-FFEA-46EB-B45F-829A846E624BQ38130301-FC70C322-B55E-47DE-8000-61B18FEF9842Q38192969-8EBB4A15-F3D5-43AD-BF74-C2829E1EE057Q38765278-0CA73A0D-6AF0-4E12-B48B-230F2E841E9DQ39030703-71F1DB34-74B7-4825-B039-FCFBA78D7804Q39138108-FAD83459-A80E-46A3-A533-7621DC551A6EQ39388200-54BDF81C-63FC-4406-A329-C88C0A19276DQ41286590-B36D7312-4268-406A-804D-80E56907C8F4Q41370609-82F057EB-76A6-41BF-8773-4C9A43CEBE17Q41593035-5ED2786F-3C71-4715-8F68-9AEE70723205Q42737828-A53A0140-F4B0-4A35-990A-9C65D4B29133Q46609677-4E4C7AD0-39F6-4B79-93BB-01E1CF6C8BF1Q58572512-0533368E-6888-4A9E-94B1-F2ED26E42655Q58790080-28D8590C-9CD9-4BE6-A666-ABA04C6D6BFAQ59145948-D70A38EB-92D7-466F-A27C-386257719986
P2860
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Immunomodulatory drugs lenalid ...... ression of adhesion molecules.
@en
Immunomodulatory drugs lenalid ...... ression of adhesion molecules.
@nl
type
label
Immunomodulatory drugs lenalid ...... ression of adhesion molecules.
@en
Immunomodulatory drugs lenalid ...... ression of adhesion molecules.
@nl
prefLabel
Immunomodulatory drugs lenalid ...... ression of adhesion molecules.
@en
Immunomodulatory drugs lenalid ...... ression of adhesion molecules.
@nl
P2093
P50
P1476
Immunomodulatory drugs lenalid ...... ression of adhesion molecules.
@en
P2093
Daniela Guasco
Luca Agnelli
Sabrina Bonomini
Vittorio Rizzoli
P304
P356
10.1016/J.EXPHEM.2012.11.005
P577
2012-11-23T00:00:00Z